Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Erythropoietin (EPO) is a hormone produced in the kidney. Its function is to stimulate the production of red cells in the bone marrow. The purpose of this research study is to demonstrate that the administration EPO to critically ill subjects in the intensive care unit (ICU) reduces the number of patients requiring red blood cell (RBC) transfusion as compared with placebo (a liquid without active medicine).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Critically ill patient admitted to the ICU

• Patient is anemic when entering the study (hemoglobin Exclusion Criteria:

• Patients with a history of blood clots (deep vein thrombosis)

• Patients with acute ischemic cardiac disease

• Patients receiving hemodialysis or peritoneal dialysis

• Patients admitted to the ICU because of acute GI bleeding

• Patients who are planned to be discharged from the ICU within 48 hours of entering the study